<DOC>
	<DOCNO>NCT01246076</DOCNO>
	<brief_summary>The purpose study determine proportion confirm response ( complete response , partial response , hematologic improvement define revise IWG criterion 12 month treatment .</brief_summary>
	<brief_title>Lenalidomide Myelodysplastic Syndrome Refractory Hypomethylating Agents</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Lenalidomide</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<criteria>Patient must able understand voluntarily sign informed consent form . Patient must ≥ 18 year old . Patient must able adhere study visit schedule protocol requirement . Patient must histologically confirm Myelodysplastic Syndrome define FAB Classification include CMML secondary MDS either : progressed time treatment hypomethylating agent fail achieve response 6 cycle progress treatment hypomethylating agent discontinue Criteria response progression define revise IWG criterion Patient must discontinue previous cancer therapy , include radiation , hormonal therapy surgery least 4 week prior treatment study . Patient must ECOG performance status ≤ 2 study entry Patient must laboratory test result within range : calculate creatinine clearance ≥ 30ml/min CockcroftGault formula total bilirubin ≤ 1.5 x ULN AST ( SGOT ) ALT ( SGPT ) ≤ 3 x ULN Patient must disease free prior malignancy least 5 year exception currently treat basal cell , squamous cell carcinoma skin , carcinoma `` situ '' cervix breast . Patient must register mandatory Revlimid REMS® program willing able comply requirement Revlimid REMS® . If female childbearing potential ( FCBP ) , patient must negative serum urine pregnancy test sensitivity least 50 mIU/mL within 10 14 day prior initiation therapy within 24 hour prior prescribe lenalidomide Cycle 1 ( prescription must fill within 7 day ) . Females reproductive potential must adhere scheduled pregnancy test require Revlimid REMS® program . A FCBP define sexually mature woman : 1 ) undergone hysterectomy bilateral oophorectomy ; 2 ) naturally postmenopausal least 24 consecutive month ( i.e. , menses time precede 24 consecutive month ) . If FCBP , patient must agree use two reliable form contraception simultaneously practice complete abstinence heterosexual intercourse follow time period relate study : 1 ) least 28 day start study drug ; 2 ) participate study ; 3 ) least 28 day discontinuation study . The two method reliable contraception must include one highly effective method ( i.e . intrauterine device ( IUD ) , hormonal [ birth control pill , injection , implant ] , tubal ligation , partner 's vasectomy ) one additional effective ( barrier ) method ( i.e . latex condom , diaphragm , cervical cap ) . FCBP must refer qualified provider contraceptive method need Patient must serious medical condition , laboratory abnormality , psychiatric illness would prevent subject signing informed consent form . Patient must pregnant breastfeeding . Patient must condition , include presence laboratory abnormality , place subject unacceptable risk he/she participate study confounds ability interpret data study . Patient must use experimental drug therapy within 28 day baseline . Patient must know hypersensitivity thalidomide . Patient must develop erythema nodosum characterize desquamating rash take thalidomide similar drug . Patient must prior use lenalidomide . Patient must concurrently use anticancer agent treatment . Patient must know seropositivity active viral infection human immunodeficiency virus ( HIV ) , hepatitis B virus ( HBV ) , hepatitis C virus ( HCV ) . Patients seropositive hepatitis B virus vaccine eligible .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2015</verification_date>
</DOC>